Clinical trial
Efficacy and Safety of BG00012 in MS
NCT00168701 · Biogen, Industry · Completed
Key facts
| NCT number | NCT00168701 |
|---|---|
| Title | Efficacy and Safety of BG00012 in MS |
| Official title | Double-Blind, Placebo-Controlled, Dose-Ranging Study to Determine the Efficacy and Safety of BG00012 in Subjects With Relapsing-Remitting Multiple Sclerosis |
| Lead sponsor | Biogen, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Sclerosis |
| Intervention type | Drug |
| Interventions | BG00012 |
| Enrollment | 260 |
| Start date | Oct 1, 2004 |
| Primary completion | Mar 31, 2006 |
| Completion | Mar 31, 2006 |
| First posted | Sep 15, 2005 |
| Last update posted | Aug 28, 2023 |
| Countries | Czechia, Germany, Hungary, Netherlands, Poland, Russia, Sweden, Switzerland, Turkey (Türkiye), United Kingdom |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: